View ValuationESSA Industries Indonesia 将来の成長Future 基準チェック /06ESSA Industries Indonesia利益と収益がそれぞれ年間1%と2.2%増加すると予測されています。EPS は年間 減少すると予想されています。自己資本利益率は 3 年後に10.7% 2.4%なると予測されています。主要情報1.0%収益成長率-2.44%EPS成長率Chemicals 収益成長21.0%収益成長率2.2%将来の株主資本利益率10.70%アナリストカバレッジLow最終更新日06 May 2026今後の成長に関する最新情報更新なしすべての更新を表示Recent updatesReported Earnings • Jul 28Second quarter 2026 earnings released: EPS: US$0.001 (vs US$0 in 2Q 2025)Second quarter 2026 results: EPS: US$0.001 (up from US$0 in 2Q 2025). Revenue: US$91.3m (up 34% from 2Q 2025). Net income: US$11.4m (up 70% from 2Q 2025). Profit margin: 13% (up from 9.9% in 2Q 2025). The increase in margin was driven by higher revenue. Revenue is forecast to grow 2.2% p.a. on average during the next 3 years, compared to a 3.6% growth forecast for the Chemicals industry in Germany.お知らせ • Jun 23PT ESSA Industries Indonesia Tbk. announces Annual dividend, payable on July 15, 2026PT ESSA Industries Indonesia Tbk. announced Annual dividend of IDR 52.0000 per share payable on July 15, 2026, ex-date on June 29, 2026 and record date on June 30, 2026.お知らせ • May 12PT ESSA Industries Indonesia Tbk., Annual General Meeting, Jun 18, 2026PT ESSA Industries Indonesia Tbk., Annual General Meeting, Jun 18, 2026.Buy Or Sell Opportunity • May 04Now 63% undervaluedThe stock has been flat over the last 90 days, currently trading at €0.0005. The fair value is estimated to be €0.0013, however this is not to be taken as a buy recommendation but rather should be used as a guide only. Revenue has declined by 25% over the last 3 years. Earnings per share has declined by 28%. Revenue is forecast to grow by 1.2% in a year. Earnings are forecast to grow by 4.1% in the next year.Reported Earnings • May 02First quarter 2026 earnings released: EPS: US$0.001 (vs US$0 in 1Q 2025)First quarter 2026 results: EPS: US$0.001 (up from US$0 in 1Q 2025). Revenue: US$95.2m (up 37% from 1Q 2025). Net income: US$18.8m (up 131% from 1Q 2025). Profit margin: 20% (up from 12% in 1Q 2025). The increase in margin was driven by higher revenue. Revenue is expected to decline by 4.2% p.a. on average during the next 2 years, while revenues in the Chemicals industry in Germany are expected to grow by 3.3%. Over the last 3 years on average, earnings per share has fallen by 28% per year but the company’s share price has increased by 10% per year, which means it is well ahead of earnings.Buy Or Sell Opportunity • Apr 10Now 38% undervalued after recent price dropOver the last 90 days, the stock has fallen 33% to €0.026. The fair value is estimated to be €0.042, however this is not to be taken as a buy recommendation but rather should be used as a guide only. Revenue has declined by 33% over the last 3 years. Earnings per share has declined by 45%. Revenue is forecast to grow by 1.2% in 2 years. Earnings are forecast to grow by 24% in the next 2 years.Recent Insider Transactions • Apr 07Insider recently sold €552k worth of stockOn the 31st of March, Theodore Rachmat sold around 14m shares on-market at roughly €0.039 per share. This transaction amounted to 1.6% of their direct individual holding at the time of the trade. In the last 3 months, they made an even bigger sale worth €2.4m. Insiders have been net sellers, collectively disposing of €4.6m more than they bought in the last 12 months.Buy Or Sell Opportunity • Mar 25Now 34% undervalued after recent price dropOver the last 90 days, the stock has fallen 98% to €0.0005. The fair value is estimated to be €0.00076, however this is not to be taken as a buy recommendation but rather should be used as a guide only. Revenue has declined by 33% over the last 3 years. Earnings per share has declined by 45%. Revenue is forecast to decline by 10% in 2 years. Earnings are forecast to decline by 0.7% in the next 2 years.Recent Insider Transactions • Mar 11Insider recently sold €1.7m worth of stockOn the 5th of March, Theodore Rachmat sold around 42m shares on-market at roughly €0.04 per share. This transaction amounted to 3.4% of their direct individual holding at the time of the trade. This was the largest sale by an insider in the last 3 months. This was the only on-market transaction from insiders over the last 12 months.Reported Earnings • Mar 09Full year 2025 earnings released: EPS: US$0.002 (vs US$0.003 in FY 2024)Full year 2025 results: EPS: US$0.002 (down from US$0.003 in FY 2024). Revenue: US$295.0m (down 2.1% from FY 2024). Net income: US$40.3m (down 11% from FY 2024). Profit margin: 14% (down from 15% in FY 2024). Revenue is expected to decline by 5.2% p.a. on average during the next 2 years, while revenues in the Chemicals industry in Germany are expected to grow by 3.2%.Reported Earnings • Oct 23Third quarter 2025 earnings released: EPS: US$0 (vs US$0.001 in 3Q 2024)Third quarter 2025 results: EPS: US$0 (down from US$0.001 in 3Q 2024). Revenue: US$62.8m (down 20% from 3Q 2024). Net income: US$6.46m (down 50% from 3Q 2024). Profit margin: 10% (down from 17% in 3Q 2024). The decrease in margin was driven by lower revenue. Revenue is forecast to stay flat during the next 3 years compared to a 2.4% growth forecast for the Chemicals industry in Germany. Over the last 3 years on average, earnings per share has fallen by 48% per year but the company’s share price has only fallen by 22% per year, which means it has not declined as severely as earnings.Reported Earnings • Jul 28Second quarter 2025 earnings released: EPS: US$0 (vs US$0.001 in 2Q 2024)Second quarter 2025 results: EPS: US$0 (down from US$0.001 in 2Q 2024). Revenue: US$68.0m (down 13% from 2Q 2024). Net income: US$6.72m (down 35% from 2Q 2024). Profit margin: 9.9% (down from 13% in 2Q 2024). The decrease in margin was driven by lower revenue. Revenue is expected to decline by 1.9% p.a. on average during the next 3 years, while revenues in the Chemicals industry in Germany are expected to grow by 3.0%. Over the last 3 years on average, earnings per share has fallen by 44% per year but the company’s share price has only fallen by 24% per year, which means it has not declined as severely as earnings.Buy Or Sell Opportunity • May 12Now 67% undervalued after recent price dropOver the last 90 days, the stock has fallen 99% to €0.0005. The fair value is estimated to be €0.0015, however this is not to be taken as a buy recommendation but rather should be used as a guide only. Revenue has declined by 24% over the last 3 years. Earnings per share has declined by 30%. Revenue is forecast to decline by 6.1% in 2 years. Earnings are forecast to decline by 1.1% in the next 2 years.New Risk • May 02New major risk - Revenue and earnings growthEarnings are forecast to decline by an average of 0.4% per year for the foreseeable future. This is considered a major risk. Ultimately, shareholders want to see a good return on their investment and that generally comes from sharing in the company's profits. If profits are expected to decline, then in most cases the share price will decline over time as well. In addition, if the company pays dividends it will also likely need to reduce or cut them, striking a dual blow to total shareholder returns. Currently, the following risks have been identified for the company: Major Risks Share price has been highly volatile over the past 3 months (25% average weekly change). Earnings are forecast to decline by an average of 0.4% per year for the foreseeable future. Minor Risk Unstable dividend paying track record with dividend experiencing an annual drop of over 20% in the past.New Risk • Apr 25New minor risk - Dividend sustainabilityThe company has an unstable dividend paying track record. The dividend has had an annual drop of over 20% in the past. Dividend yield: 1.6% This is considered a minor risk. If the company has cut or reduced its dividend in the past, it may be a sign that the underlying business is too cyclical to consistently maintain or grow the dividend over the long-term. It may also indicate the company prioritizes other outcomes instead of maintaining the dividend. For dividend paying companies, any reduction in the dividend can significantly impact the share price. Currently, the following risks have been identified for the company: Major Risks Share price has been highly volatile over the past 3 months (23% average weekly change). Earnings are forecast to decline by an average of 2.3% per year for the foreseeable future. Minor Risk Unstable dividend paying track record with dividend experiencing an annual drop of over 20% in the past.New Risk • Apr 24New major risk - Revenue and earnings growthEarnings are forecast to decline by an average of 2.3% per year for the foreseeable future. This is considered a major risk. Ultimately, shareholders want to see a good return on their investment and that generally comes from sharing in the company's profits. If profits are expected to decline, then in most cases the share price will decline over time as well. In addition, if the company pays dividends it will also likely need to reduce or cut them, striking a dual blow to total shareholder returns. Currently, the following risks have been identified for the company: Major Risks Share price has been highly volatile over the past 3 months (24% average weekly change). Earnings are forecast to decline by an average of 2.3% per year for the foreseeable future.お知らせ • Apr 22PT ESSA Industries Indonesia Tbk. announces Annual dividend, payable on May 16, 2025PT ESSA Industries Indonesia Tbk. announced Annual dividend of IDR 10.0000 per share payable on May 16, 2025, ex-date on April 28, 2025 and record date on April 29, 2025.お知らせ • Mar 04PT ESSA Industries Indonesia Tbk., Annual General Meeting, Apr 09, 2025PT ESSA Industries Indonesia Tbk., Annual General Meeting, Apr 09, 2025. Location: jakarta IndonesiaReported Earnings • Feb 24Full year 2024 earnings released: EPS: US$0.003 (vs US$0.002 in FY 2023)Full year 2024 results: EPS: US$0.003 (up from US$0.002 in FY 2023). Revenue: US$301.4m (down 13% from FY 2023). Net income: US$45.2m (up 31% from FY 2023). Profit margin: 15% (up from 10.0% in FY 2023). The increase in margin was driven by lower expenses. Over the last 3 years on average, earnings per share has fallen by 14% per year but the company’s share price has increased by 13% per year, which means it is well ahead of earnings.Reported Earnings • Oct 22Third quarter 2024 earnings released: EPS: US$0.001 (vs US$0 in 3Q 2023)Third quarter 2024 results: EPS: US$0.001 (up from US$0 in 3Q 2023). Revenue: US$78.5m (up 22% from 3Q 2023). Net income: US$13.0m (up 124% from 3Q 2023). Profit margin: 17% (up from 9.0% in 3Q 2023). The increase in margin was driven by higher revenue. Revenue is expected to decline by 6.8% p.a. on average during the next 3 years, while revenues in the Chemicals industry in Germany are expected to grow by 4.1%. Over the last 3 years on average, earnings per share has increased by 4% per year but the company’s share price has increased by 26% per year, which means it is tracking significantly ahead of earnings growth.New Risk • Oct 18New major risk - Revenue and earnings growthEarnings are forecast to decline by an average of 20% per year for the foreseeable future. This is considered a major risk. Ultimately, shareholders want to see a good return on their investment and that generally comes from sharing in the company's profits. If profits are expected to decline, then in most cases the share price will decline over time as well. In addition, if the company pays dividends it will also likely need to reduce or cut them, striking a dual blow to total shareholder returns. Currently, the following risks have been identified for the company: Major Risks Share price has been highly volatile over the past 3 months (21% average weekly change). Earnings are forecast to decline by an average of 20% per year for the foreseeable future.Buy Or Sell Opportunity • Oct 10Now 28% undervaluedOver the last 90 days, the stock has risen 15% to €0.05. The fair value is estimated to be €0.069, however this is not to be taken as a buy recommendation but rather should be used as a guide only. Revenue has grown by 5.8% over the last 3 years. Meanwhile, the company has become profitable.Buy Or Sell Opportunity • Jul 16Now 28% undervaluedOver the last 90 days, the stock has risen 16% to €0.043. The fair value is estimated to be €0.06, however this is not to be taken as a buy recommendation but rather should be used as a guide only. Revenue has grown by 5.8% over the last 3 years. Meanwhile, the company has become profitable. Revenue is forecast to grow by 6.6% in a year. Earnings are forecast to grow by 12% in the next year.Reported Earnings • Jul 14Second quarter 2024 earnings released: EPS: US$0.001 (vs US$0 in 2Q 2023)Second quarter 2024 results: EPS: US$0.001 (up from US$0 in 2Q 2023). Revenue: US$77.8m (down 3.2% from 2Q 2023). Net income: US$10.4m (up US$9.52m from 2Q 2023). Profit margin: 13% (up from 1.1% in 2Q 2023). The increase in margin was driven by lower expenses. Revenue is forecast to stay flat during the next 2 years compared to a 4.4% growth forecast for the Chemicals industry in Germany. Over the last 3 years on average, earnings per share has increased by 25% per year but the company’s share price has increased by 38% per year, which means it is tracking significantly ahead of earnings growth.Buy Or Sell Opportunity • May 13Now 32% undervaluedOver the last 90 days, the stock has risen 108% to €0.053. The fair value is estimated to be €0.078, however this is not to be taken as a buy recommendation but rather should be used as a guide only. Revenue has grown by 18% over the last 3 years. Meanwhile, the company has become profitable. Revenue is forecast to grow by 7.6% in a year. Earnings are forecast to grow by 45% in the next year.Reported Earnings • Apr 25First quarter 2024 earnings released: EPS: US$0.001 (vs US$0 in 1Q 2023)First quarter 2024 results: EPS: US$0.001 (up from US$0 in 1Q 2023). Revenue: US$73.8m (down 16% from 1Q 2023). Net income: US$10.2m (up 228% from 1Q 2023). Profit margin: 14% (up from 3.5% in 1Q 2023). The increase in margin was driven by lower expenses. Revenue is forecast to stay flat during the next 2 years compared to a 3.7% growth forecast for the Chemicals industry in Germany. Over the last 3 years on average, earnings per share has increased by 44% per year but the company’s share price has only increased by 29% per year, which means it is significantly lagging earnings growth.New Risk • Apr 03New major risk - Share price stabilityThe company's share price has been highly volatile over the past 3 months. It is more volatile than 90% of German stocks, typically moving 14% a week. This is considered a major risk. Share price volatility increases the risk of potential losses in the short-term as the stock tends to have larger drops in price more frequently than other stocks. It may also indicate the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. Currently, the following risks have been identified for the company: Major Risk Share price has been highly volatile over the past 3 months (14% average weekly change). Minor Risk Profit margins are more than 30% lower than last year (10% net profit margin).お知らせ • Feb 13PT ESSA Industries Indonesia Tbk., Annual General Meeting, Mar 20, 2024PT ESSA Industries Indonesia Tbk., Annual General Meeting, Mar 20, 2024.Reported Earnings • Feb 05Full year 2023 earnings released: EPS: US$0.002 (vs US$0.009 in FY 2022)Full year 2023 results: EPS: US$0.002 (down from US$0.009 in FY 2022). Revenue: US$345.0m (down 53% from FY 2022). Net income: US$34.6m (down 75% from FY 2022). Profit margin: 10.0% (down from 19% in FY 2022). The decrease in margin was driven by lower revenue. Revenue is forecast to stay flat during the next 2 years compared to a 2.7% growth forecast for the Chemicals industry in Germany. Over the last 3 years on average, earnings per share has increased by 66% per year but the company’s share price has only increased by 45% per year, which means it is significantly lagging earnings growth.New Risk • Jan 02New major risk - Revenue and earnings growthEarnings are forecast to decline by an average of 24% per year for the foreseeable future. This is considered a major risk. Ultimately, shareholders want to see a good return on their investment and that generally comes from sharing in the company's profits. If profits are expected to decline, then in most cases the share price will decline over time as well. In addition, if the company pays dividends it will also likely need to reduce or cut them, striking a dual blow to total shareholder returns. Currently, the following risks have been identified for the company: Major Risk Earnings are forecast to decline by an average of 24% per year for the foreseeable future. Minor Risks Dividend is not well covered by earnings (116% payout ratio). Share price has been volatile over the past 3 months (8.9% average weekly change). Profit margins are more than 30% lower than last year (11% net profit margin). Shareholders have been diluted in the past year (10.0% increase in shares outstanding).Recent Insider Transactions • Dec 31Insider recently bought €3.0m worth of stockOn the 22nd of December, Garibaldi Thohir bought around 99m shares on-market at roughly €0.031 per share. This transaction amounted to 12% of their direct individual holding at the time of the trade. This was the largest purchase by an insider in the last 3 months. This was the only on-market transaction from insiders over the last 12 months.Reported Earnings • Oct 20Third quarter 2023 earnings released: EPS: US$0 (vs US$0.003 in 3Q 2022)Third quarter 2023 results: EPS: US$0 (down from US$0.003 in 3Q 2022). Revenue: US$64.5m (down 69% from 3Q 2022). Net income: US$5.79m (down 85% from 3Q 2022). Profit margin: 9.0% (down from 18% in 3Q 2022). The decrease in margin was driven by lower revenue. Revenue is expected to decline by 10% p.a. on average during the next 3 years, while revenues in the Chemicals industry in Germany are expected to grow by 1.9%. Over the last 3 years on average, earnings per share has increased by 86% per year but the company’s share price has increased by 129% per year, which means it is tracking significantly ahead of earnings growth.Buying Opportunity • Aug 01Now 29% undervalued after recent price dropOver the last 90 days, the stock is down 6.1%. The fair value is estimated to be €0.043, however this is not to be taken as a buy recommendation but rather should be used as a guide only. Revenue has grown by 50% over the last 3 years. Meanwhile, the company has become profitable. Revenue is forecast to decline by 29% in 2 years. Earnings is forecast to decline by 17% in the next 2 years.Reported Earnings • Jul 30Second quarter 2023 earnings released: EPS: US$0 (vs US$0.003 in 2Q 2022)Second quarter 2023 results: EPS: US$0 (down from US$0.003 in 2Q 2022). Revenue: US$80.3m (down 58% from 2Q 2022). Net income: US$863.6k (down 98% from 2Q 2022). Profit margin: 1.1% (down from 21% in 2Q 2022). The decrease in margin was driven by lower revenue. Revenue is expected to decline by 13% p.a. on average during the next 3 years, while revenues in the Chemicals industry in Germany are expected to grow by 1.3%. Over the last 3 years on average, earnings per share has increased by 104% per year but the company’s share price has increased by 112% per year, which means it is tracking significantly ahead of earnings growth.Reported Earnings • Apr 30First quarter 2023 earnings released: EPS: US$0 (vs US$0.002 in 1Q 2022)First quarter 2023 results: EPS: US$0 (down from US$0.002 in 1Q 2022). Revenue: US$87.8m (down 45% from 1Q 2022). Net income: US$3.11m (down 88% from 1Q 2022). Profit margin: 3.5% (down from 16% in 1Q 2022). The decrease in margin was driven by lower revenue. Revenue is expected to decline by 8.7% p.a. on average during the next 3 years, while revenues in the Chemicals industry in Germany are expected to grow by 1.7%. Over the last 3 years on average, earnings per share has increased by 116% per year whereas the company’s share price has increased by 113% per year.Upcoming Dividend • Mar 21Upcoming dividend of Rp45.00 per share at 0.5% yieldEligible shareholders must have bought the stock before 28 March 2023. Payment date: 05 April 2023. Payout ratio is a comfortable 4.8% and this is well supported by cash flows. Trailing yield: 0.5%. Lower than top quartile of German dividend payers (4.9%). Lower than average of industry peers (5.8%).Reported Earnings • Feb 22Full year 2022 earnings released: EPS: US$0.009 (vs US$0.001 in FY 2021)Full year 2022 results: EPS: US$0.009 (up from US$0.001 in FY 2021). Revenue: US$731.5m (up 141% from FY 2021). Net income: US$138.8m (up US$124.9m from FY 2021). Profit margin: 19% (up from 4.6% in FY 2021). The increase in margin was driven by higher revenue. Revenue is expected to decline by 15% p.a. on average during the next 3 years, while revenues in the Chemicals industry in Germany are expected to grow by 1.4%. Over the last 3 years on average, earnings per share has increased by 119% per year but the company’s share price has only increased by 80% per year, which means it is significantly lagging earnings growth.お知らせ • Feb 11PT Surya Esa Perkasa Tbk, Annual General Meeting, Mar 15, 2023PT Surya Esa Perkasa Tbk, Annual General Meeting, Mar 15, 2023, at 15:00 SE Asia Standard Time.お知らせ • Jan 04PT Surya Esa Perkasa Tbk agreed to acquire an additional unknown stake in PT Panca Amara Utama from Garibaldi Thohir.PT Surya Esa Perkasa Tbk agreed to acquire an additional unknown stake in PT Panca Amara Utama from Garibaldi Thohir on January 2, 2023. The proceeds from private placement were used for this acquisition.Board Change • Nov 16No independent directorsFollowing the recent departure of a director, there are no independent directors on the board. The company's board is composed of: No independent directors. 5 non-independent directors. Independent President Commissioner Hamid Awaluddin was the last independent director to join the board, commencing their role in 2012. The company's lack of independent directors is a risk according to the Simply Wall St Risk Model.Reported Earnings • Oct 12Third quarter 2022 earnings released: EPS: US$0.003 (vs US$0.001 in 3Q 2021)Third quarter 2022 results: EPS: US$0.003 (up from US$0.001 in 3Q 2021). Revenue: US$206.1m (up 103% from 3Q 2021). Net income: US$37.7m (up 100% from 3Q 2021). Profit margin: 18% (in line with 3Q 2021). Revenue is expected to decline by 5.5% p.a. on average during the next 3 years, while revenues in the Chemicals industry in Germany are expected to grow by 1.3%. Over the last 3 years on average, earnings per share has increased by 88% per year but the company’s share price has only increased by 73% per year, which means it is significantly lagging earnings growth.Reported Earnings • Jul 28Second quarter 2022 earnings releasedSecond quarter 2022 results: Revenue: US$191.9m (up 173% from 2Q 2021). Net income: US$41.0m (up US$58.1m from 2Q 2021). Profit margin: 21% (up from net loss in 2Q 2021). The move to profitability was driven by higher revenue. Over the next year, revenue is forecast to grow 27%, compared to a 7.3% growth forecast for the industry in Germany. Over the last 3 years on average, earnings per share has increased by 31% per year but the company’s share price has increased by 69% per year, which means it is tracking significantly ahead of earnings growth.Buying Opportunity • Jul 05Now 31% undervalued after recent price dropOver the last 90 days, the stock is down 38%. The fair value is estimated to be €0.072, however this is not to be taken as a buy recommendation but rather should be used as a guide only. Revenue has grown by 15% over the last 3 years. Meanwhile, the company has become profitable. Revenue is forecast to grow by 50% in 2 years. Earnings is forecast to grow by 233% in the next 2 years.Buying Opportunity • Jun 17Now 20% undervaluedOver the last 90 days, the stock is up 13%. The fair value is estimated to be €0.061, however this is not to be taken as a buy recommendation but rather should be used as a guide only. Revenue has grown by 15% over the last 3 years. Meanwhile, the company has become profitable. Revenue is forecast to grow by 50% in 2 years. Earnings is forecast to grow by 233% in the next 2 years.Reported Earnings • Jun 01First quarter 2022 earnings released: EPS: US$0.002 (vs US$0 in 1Q 2021)First quarter 2022 results: EPS: US$0.002 (up from US$0 in 1Q 2021). Revenue: US$159.0m (up 132% from 1Q 2021). Net income: US$25.9m (up 304% from 1Q 2021). Profit margin: 16% (up from 9.4% in 1Q 2021). The increase in margin was driven by higher revenue. Over the next year, revenue is forecast to grow 80%, compared to a 52% growth forecast for the industry in Germany. Over the last 3 years on average, earnings per share has fallen by 48% per year but the company’s share price has increased by 72% per year, which means it is well ahead of earnings.Board Change • Apr 27No independent directorsFollowing the recent departure of a director, there are no independent directors on the board. The company's board is composed of: No independent directors. 5 non-independent directors. Independent Commissioner Ida Bagus Supancana was the last independent director to join the board, commencing their role in 2011. The company's lack of independent directors is a risk according to the Simply Wall St Risk Model.Buying Opportunity • Mar 09Now 22% undervaluedOver the last 90 days, the stock is up 131%. The fair value is estimated to be US$0.052, however this is not to be taken as a buy recommendation but rather should be used as a guide only. Revenue has grown by 13% per annum over the last 3 years. The company has become profitable over the last year.Reported Earnings • Nov 27Third quarter 2021 earnings: EPS in line with analyst expectations despite revenue beatThird quarter 2021 results: EPS: US$0.001 (up from US$0.001 loss in 3Q 2020). Revenue: US$101.6m (up 261% from 3Q 2020). Net income: US$18.9m (up US$26.6m from 3Q 2020). Profit margin: 19% (up from net loss in 3Q 2020). The move to profitability was driven by higher revenue. Revenue exceeded analyst estimates by 14%. Over the last 3 years on average, the company's share price growth rate has exceeded its earnings growth rate by 122 percentage points per year, which is a significant difference in performance.Reported Earnings • Aug 31Second quarter 2021 earnings released: US$0.001 loss per share (vs US$0.001 loss in 2Q 2020)The company reported a decent second quarter result with improved revenues, although losses increased and control over costs was weaker. Second quarter 2021 results: Revenue: US$70.4m (up 114% from 2Q 2020). Net loss: US$17.1m (loss widened 120% from 2Q 2020). Over the last 3 years on average, the company's share price growth rate has exceeded its earnings growth rate by 148 percentage points per year, which is a significant difference in performance.Reported Earnings • Oct 29Third quarter earnings releasedOver the last 12 months the company has reported total losses of US$16.4m, with earnings decreasing by US$43.0m from the prior year. Total revenue was US$177.4m over the last 12 months, down 27% from the prior year.お知らせ • Sep 21PT Surya Esa Perkasa Tbk(IDX:ESSA) dropped from S&P Global BMI IndexPT Surya Esa Perkasa Tbk(IDX:ESSA) dropped from S&P Global BMI Index業績と収益の成長予測BST:71S - アナリストの将来予測と過去の財務データ ( )USD Millions日付収益収益フリー・キャッシュフロー営業活動によるキャッシュ平均アナリスト数12/31/202840561122126112/31/202733459128112312/31/20263806916014026/30/202634456139147N/A3/31/202632151123131N/A12/31/20252954096104N/A9/30/2025272337988N/A6/30/202528739106114N/A3/31/202529743115121N/A12/31/202430145138143N/A9/30/202434258148153N/A6/30/202432851131135N/A3/31/202433142118122N/A12/31/202334535149151N/A9/30/202340744187186N/A6/30/202354976262263N/A3/31/2023660116332333N/A12/31/2022731139317319N/A9/30/2022620110253256N/A6/30/202251592201204N/A3/31/202239433130132N/A12/31/2021303149092N/A9/30/2021292499100N/A6/30/2021219-235253N/A3/31/2021181-143942N/A12/31/2020176-194247N/A9/30/2020177-163744N/A6/30/2020201-85762N/A3/31/2020227-1N/A86N/A12/31/20192223N/A88N/A9/30/201924227N/A103N/A6/30/201924234N/A76N/A3/31/201919336N/A49N/A12/31/201814834N/A28N/A9/30/20188613N/A13N/A6/30/2018425N/A17N/A3/31/2018405N/A10N/A12/31/2017343N/A4N/A9/30/2017301N/A-5N/A6/30/2017291N/A-9N/A3/31/2017290N/A-18N/A12/31/2016290N/A-12N/A9/30/2016320N/A-27N/A6/30/2016342N/A-20N/A3/31/2016383N/A-10N/A12/31/2015415N/A-6N/A9/30/2015385N/A6N/Aもっと見るアナリストによる今後の成長予測収入対貯蓄率: 71Sの予測収益成長率 (年間1% ) は 貯蓄率 ( 1.9% ) を下回っています。収益対市場: 71Sの収益 ( 1% ) German市場 ( 15.4% ) よりも低い成長が予測されています。高成長収益: 71Sの収益は増加すると予測されていますが、大幅には増加しません。収益対市場: 71Sの収益 ( 2.2% ) German市場 ( 6.7% ) よりも低い成長が予測されています。高い収益成長: 71Sの収益 ( 2.2% ) 20%よりも低い成長が予測されています。一株当たり利益成長率予想将来の株主資本利益率将来のROE: 71Sの 自己資本利益率 は、3年後には低くなると予測されています ( 10.7 %)。成長企業の発掘7D1Y7D1Y7D1YMaterials 業界の高成長企業。View Past Performance企業分析と財務データの現状データ最終更新日（UTC時間）企業分析2026/07/31 23:09終値2026/07/31 00:00収益2026/06/30年間収益2025/12/31データソース企業分析に使用したデータはS&P Global Market Intelligence LLC のものです。本レポートを作成するための分析モデルでは、以下のデータを使用しています。データは正規化されているため、ソースが利用可能になるまでに時間がかかる場合があります。パッケージデータタイムフレーム米国ソース例会社財務10年損益計算書キャッシュ・フロー計算書貸借対照表SECフォーム10-KSECフォーム10-Qアナリストのコンセンサス予想+プラス3年予想財務アナリストの目標株価アナリストリサーチレポートBlue Matrix市場価格30年株価配当、分割、措置ICEマーケットデータSECフォームS-1所有権10年トップ株主インサイダー取引SECフォーム4SECフォーム13Dマネジメント10年リーダーシップ・チーム取締役会SECフォーム10-KSECフォームDEF 14A主な進展10年会社からのお知らせSECフォーム8-K* 米国証券を対象とした例であり、非米国証券については、同等の規制書式および情報源を使用。特に断りのない限り、すべての財務データは1年ごとの期間に基づいていますが、四半期ごとに更新されます。これは、TTM（Trailing Twelve Month）またはLTM（Last Twelve Month）データとして知られています。詳細はこちら。分析モデルとスノーフレークこのレポートを生成するために使用した分析モデルの詳細は、当社のGitHubページでご覧いただけます。また、レポートの活用方法に関するガイドやYouTubeのチュートリアルも用意しています。シンプリー・ウォールストリート分析モデルを設計・構築した世界トップクラスのチームについてご紹介します。業界およびセクターの指標私たちの業界とセクションの指標は、Simply Wall Stによって6時間ごとに計算されます。アナリスト筋PT ESSA Industries Indonesia Tbk. 3 これらのアナリストのうち、弊社レポートのインプットとして使用した売上高または利益の予想を提出したのは、 。アナリストの投稿は一日中更新されます。6 アナリスト機関Stifanus SulistyoCLSAAhmad UsmanNomura Securities Co. Ltd.Heng Siong KongNomura Securities Co. Ltd.3 その他のアナリストを表示
Reported Earnings • Jul 28Second quarter 2026 earnings released: EPS: US$0.001 (vs US$0 in 2Q 2025)Second quarter 2026 results: EPS: US$0.001 (up from US$0 in 2Q 2025). Revenue: US$91.3m (up 34% from 2Q 2025). Net income: US$11.4m (up 70% from 2Q 2025). Profit margin: 13% (up from 9.9% in 2Q 2025). The increase in margin was driven by higher revenue. Revenue is forecast to grow 2.2% p.a. on average during the next 3 years, compared to a 3.6% growth forecast for the Chemicals industry in Germany.
お知らせ • Jun 23PT ESSA Industries Indonesia Tbk. announces Annual dividend, payable on July 15, 2026PT ESSA Industries Indonesia Tbk. announced Annual dividend of IDR 52.0000 per share payable on July 15, 2026, ex-date on June 29, 2026 and record date on June 30, 2026.
お知らせ • May 12PT ESSA Industries Indonesia Tbk., Annual General Meeting, Jun 18, 2026PT ESSA Industries Indonesia Tbk., Annual General Meeting, Jun 18, 2026.
Buy Or Sell Opportunity • May 04Now 63% undervaluedThe stock has been flat over the last 90 days, currently trading at €0.0005. The fair value is estimated to be €0.0013, however this is not to be taken as a buy recommendation but rather should be used as a guide only. Revenue has declined by 25% over the last 3 years. Earnings per share has declined by 28%. Revenue is forecast to grow by 1.2% in a year. Earnings are forecast to grow by 4.1% in the next year.
Reported Earnings • May 02First quarter 2026 earnings released: EPS: US$0.001 (vs US$0 in 1Q 2025)First quarter 2026 results: EPS: US$0.001 (up from US$0 in 1Q 2025). Revenue: US$95.2m (up 37% from 1Q 2025). Net income: US$18.8m (up 131% from 1Q 2025). Profit margin: 20% (up from 12% in 1Q 2025). The increase in margin was driven by higher revenue. Revenue is expected to decline by 4.2% p.a. on average during the next 2 years, while revenues in the Chemicals industry in Germany are expected to grow by 3.3%. Over the last 3 years on average, earnings per share has fallen by 28% per year but the company’s share price has increased by 10% per year, which means it is well ahead of earnings.
Buy Or Sell Opportunity • Apr 10Now 38% undervalued after recent price dropOver the last 90 days, the stock has fallen 33% to €0.026. The fair value is estimated to be €0.042, however this is not to be taken as a buy recommendation but rather should be used as a guide only. Revenue has declined by 33% over the last 3 years. Earnings per share has declined by 45%. Revenue is forecast to grow by 1.2% in 2 years. Earnings are forecast to grow by 24% in the next 2 years.
Recent Insider Transactions • Apr 07Insider recently sold €552k worth of stockOn the 31st of March, Theodore Rachmat sold around 14m shares on-market at roughly €0.039 per share. This transaction amounted to 1.6% of their direct individual holding at the time of the trade. In the last 3 months, they made an even bigger sale worth €2.4m. Insiders have been net sellers, collectively disposing of €4.6m more than they bought in the last 12 months.
Buy Or Sell Opportunity • Mar 25Now 34% undervalued after recent price dropOver the last 90 days, the stock has fallen 98% to €0.0005. The fair value is estimated to be €0.00076, however this is not to be taken as a buy recommendation but rather should be used as a guide only. Revenue has declined by 33% over the last 3 years. Earnings per share has declined by 45%. Revenue is forecast to decline by 10% in 2 years. Earnings are forecast to decline by 0.7% in the next 2 years.
Recent Insider Transactions • Mar 11Insider recently sold €1.7m worth of stockOn the 5th of March, Theodore Rachmat sold around 42m shares on-market at roughly €0.04 per share. This transaction amounted to 3.4% of their direct individual holding at the time of the trade. This was the largest sale by an insider in the last 3 months. This was the only on-market transaction from insiders over the last 12 months.
Reported Earnings • Mar 09Full year 2025 earnings released: EPS: US$0.002 (vs US$0.003 in FY 2024)Full year 2025 results: EPS: US$0.002 (down from US$0.003 in FY 2024). Revenue: US$295.0m (down 2.1% from FY 2024). Net income: US$40.3m (down 11% from FY 2024). Profit margin: 14% (down from 15% in FY 2024). Revenue is expected to decline by 5.2% p.a. on average during the next 2 years, while revenues in the Chemicals industry in Germany are expected to grow by 3.2%.
Reported Earnings • Oct 23Third quarter 2025 earnings released: EPS: US$0 (vs US$0.001 in 3Q 2024)Third quarter 2025 results: EPS: US$0 (down from US$0.001 in 3Q 2024). Revenue: US$62.8m (down 20% from 3Q 2024). Net income: US$6.46m (down 50% from 3Q 2024). Profit margin: 10% (down from 17% in 3Q 2024). The decrease in margin was driven by lower revenue. Revenue is forecast to stay flat during the next 3 years compared to a 2.4% growth forecast for the Chemicals industry in Germany. Over the last 3 years on average, earnings per share has fallen by 48% per year but the company’s share price has only fallen by 22% per year, which means it has not declined as severely as earnings.
Reported Earnings • Jul 28Second quarter 2025 earnings released: EPS: US$0 (vs US$0.001 in 2Q 2024)Second quarter 2025 results: EPS: US$0 (down from US$0.001 in 2Q 2024). Revenue: US$68.0m (down 13% from 2Q 2024). Net income: US$6.72m (down 35% from 2Q 2024). Profit margin: 9.9% (down from 13% in 2Q 2024). The decrease in margin was driven by lower revenue. Revenue is expected to decline by 1.9% p.a. on average during the next 3 years, while revenues in the Chemicals industry in Germany are expected to grow by 3.0%. Over the last 3 years on average, earnings per share has fallen by 44% per year but the company’s share price has only fallen by 24% per year, which means it has not declined as severely as earnings.
Buy Or Sell Opportunity • May 12Now 67% undervalued after recent price dropOver the last 90 days, the stock has fallen 99% to €0.0005. The fair value is estimated to be €0.0015, however this is not to be taken as a buy recommendation but rather should be used as a guide only. Revenue has declined by 24% over the last 3 years. Earnings per share has declined by 30%. Revenue is forecast to decline by 6.1% in 2 years. Earnings are forecast to decline by 1.1% in the next 2 years.
New Risk • May 02New major risk - Revenue and earnings growthEarnings are forecast to decline by an average of 0.4% per year for the foreseeable future. This is considered a major risk. Ultimately, shareholders want to see a good return on their investment and that generally comes from sharing in the company's profits. If profits are expected to decline, then in most cases the share price will decline over time as well. In addition, if the company pays dividends it will also likely need to reduce or cut them, striking a dual blow to total shareholder returns. Currently, the following risks have been identified for the company: Major Risks Share price has been highly volatile over the past 3 months (25% average weekly change). Earnings are forecast to decline by an average of 0.4% per year for the foreseeable future. Minor Risk Unstable dividend paying track record with dividend experiencing an annual drop of over 20% in the past.
New Risk • Apr 25New minor risk - Dividend sustainabilityThe company has an unstable dividend paying track record. The dividend has had an annual drop of over 20% in the past. Dividend yield: 1.6% This is considered a minor risk. If the company has cut or reduced its dividend in the past, it may be a sign that the underlying business is too cyclical to consistently maintain or grow the dividend over the long-term. It may also indicate the company prioritizes other outcomes instead of maintaining the dividend. For dividend paying companies, any reduction in the dividend can significantly impact the share price. Currently, the following risks have been identified for the company: Major Risks Share price has been highly volatile over the past 3 months (23% average weekly change). Earnings are forecast to decline by an average of 2.3% per year for the foreseeable future. Minor Risk Unstable dividend paying track record with dividend experiencing an annual drop of over 20% in the past.
New Risk • Apr 24New major risk - Revenue and earnings growthEarnings are forecast to decline by an average of 2.3% per year for the foreseeable future. This is considered a major risk. Ultimately, shareholders want to see a good return on their investment and that generally comes from sharing in the company's profits. If profits are expected to decline, then in most cases the share price will decline over time as well. In addition, if the company pays dividends it will also likely need to reduce or cut them, striking a dual blow to total shareholder returns. Currently, the following risks have been identified for the company: Major Risks Share price has been highly volatile over the past 3 months (24% average weekly change). Earnings are forecast to decline by an average of 2.3% per year for the foreseeable future.
お知らせ • Apr 22PT ESSA Industries Indonesia Tbk. announces Annual dividend, payable on May 16, 2025PT ESSA Industries Indonesia Tbk. announced Annual dividend of IDR 10.0000 per share payable on May 16, 2025, ex-date on April 28, 2025 and record date on April 29, 2025.
お知らせ • Mar 04PT ESSA Industries Indonesia Tbk., Annual General Meeting, Apr 09, 2025PT ESSA Industries Indonesia Tbk., Annual General Meeting, Apr 09, 2025. Location: jakarta Indonesia
Reported Earnings • Feb 24Full year 2024 earnings released: EPS: US$0.003 (vs US$0.002 in FY 2023)Full year 2024 results: EPS: US$0.003 (up from US$0.002 in FY 2023). Revenue: US$301.4m (down 13% from FY 2023). Net income: US$45.2m (up 31% from FY 2023). Profit margin: 15% (up from 10.0% in FY 2023). The increase in margin was driven by lower expenses. Over the last 3 years on average, earnings per share has fallen by 14% per year but the company’s share price has increased by 13% per year, which means it is well ahead of earnings.
Reported Earnings • Oct 22Third quarter 2024 earnings released: EPS: US$0.001 (vs US$0 in 3Q 2023)Third quarter 2024 results: EPS: US$0.001 (up from US$0 in 3Q 2023). Revenue: US$78.5m (up 22% from 3Q 2023). Net income: US$13.0m (up 124% from 3Q 2023). Profit margin: 17% (up from 9.0% in 3Q 2023). The increase in margin was driven by higher revenue. Revenue is expected to decline by 6.8% p.a. on average during the next 3 years, while revenues in the Chemicals industry in Germany are expected to grow by 4.1%. Over the last 3 years on average, earnings per share has increased by 4% per year but the company’s share price has increased by 26% per year, which means it is tracking significantly ahead of earnings growth.
New Risk • Oct 18New major risk - Revenue and earnings growthEarnings are forecast to decline by an average of 20% per year for the foreseeable future. This is considered a major risk. Ultimately, shareholders want to see a good return on their investment and that generally comes from sharing in the company's profits. If profits are expected to decline, then in most cases the share price will decline over time as well. In addition, if the company pays dividends it will also likely need to reduce or cut them, striking a dual blow to total shareholder returns. Currently, the following risks have been identified for the company: Major Risks Share price has been highly volatile over the past 3 months (21% average weekly change). Earnings are forecast to decline by an average of 20% per year for the foreseeable future.
Buy Or Sell Opportunity • Oct 10Now 28% undervaluedOver the last 90 days, the stock has risen 15% to €0.05. The fair value is estimated to be €0.069, however this is not to be taken as a buy recommendation but rather should be used as a guide only. Revenue has grown by 5.8% over the last 3 years. Meanwhile, the company has become profitable.
Buy Or Sell Opportunity • Jul 16Now 28% undervaluedOver the last 90 days, the stock has risen 16% to €0.043. The fair value is estimated to be €0.06, however this is not to be taken as a buy recommendation but rather should be used as a guide only. Revenue has grown by 5.8% over the last 3 years. Meanwhile, the company has become profitable. Revenue is forecast to grow by 6.6% in a year. Earnings are forecast to grow by 12% in the next year.
Reported Earnings • Jul 14Second quarter 2024 earnings released: EPS: US$0.001 (vs US$0 in 2Q 2023)Second quarter 2024 results: EPS: US$0.001 (up from US$0 in 2Q 2023). Revenue: US$77.8m (down 3.2% from 2Q 2023). Net income: US$10.4m (up US$9.52m from 2Q 2023). Profit margin: 13% (up from 1.1% in 2Q 2023). The increase in margin was driven by lower expenses. Revenue is forecast to stay flat during the next 2 years compared to a 4.4% growth forecast for the Chemicals industry in Germany. Over the last 3 years on average, earnings per share has increased by 25% per year but the company’s share price has increased by 38% per year, which means it is tracking significantly ahead of earnings growth.
Buy Or Sell Opportunity • May 13Now 32% undervaluedOver the last 90 days, the stock has risen 108% to €0.053. The fair value is estimated to be €0.078, however this is not to be taken as a buy recommendation but rather should be used as a guide only. Revenue has grown by 18% over the last 3 years. Meanwhile, the company has become profitable. Revenue is forecast to grow by 7.6% in a year. Earnings are forecast to grow by 45% in the next year.
Reported Earnings • Apr 25First quarter 2024 earnings released: EPS: US$0.001 (vs US$0 in 1Q 2023)First quarter 2024 results: EPS: US$0.001 (up from US$0 in 1Q 2023). Revenue: US$73.8m (down 16% from 1Q 2023). Net income: US$10.2m (up 228% from 1Q 2023). Profit margin: 14% (up from 3.5% in 1Q 2023). The increase in margin was driven by lower expenses. Revenue is forecast to stay flat during the next 2 years compared to a 3.7% growth forecast for the Chemicals industry in Germany. Over the last 3 years on average, earnings per share has increased by 44% per year but the company’s share price has only increased by 29% per year, which means it is significantly lagging earnings growth.
New Risk • Apr 03New major risk - Share price stabilityThe company's share price has been highly volatile over the past 3 months. It is more volatile than 90% of German stocks, typically moving 14% a week. This is considered a major risk. Share price volatility increases the risk of potential losses in the short-term as the stock tends to have larger drops in price more frequently than other stocks. It may also indicate the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. Currently, the following risks have been identified for the company: Major Risk Share price has been highly volatile over the past 3 months (14% average weekly change). Minor Risk Profit margins are more than 30% lower than last year (10% net profit margin).
お知らせ • Feb 13PT ESSA Industries Indonesia Tbk., Annual General Meeting, Mar 20, 2024PT ESSA Industries Indonesia Tbk., Annual General Meeting, Mar 20, 2024.
Reported Earnings • Feb 05Full year 2023 earnings released: EPS: US$0.002 (vs US$0.009 in FY 2022)Full year 2023 results: EPS: US$0.002 (down from US$0.009 in FY 2022). Revenue: US$345.0m (down 53% from FY 2022). Net income: US$34.6m (down 75% from FY 2022). Profit margin: 10.0% (down from 19% in FY 2022). The decrease in margin was driven by lower revenue. Revenue is forecast to stay flat during the next 2 years compared to a 2.7% growth forecast for the Chemicals industry in Germany. Over the last 3 years on average, earnings per share has increased by 66% per year but the company’s share price has only increased by 45% per year, which means it is significantly lagging earnings growth.
New Risk • Jan 02New major risk - Revenue and earnings growthEarnings are forecast to decline by an average of 24% per year for the foreseeable future. This is considered a major risk. Ultimately, shareholders want to see a good return on their investment and that generally comes from sharing in the company's profits. If profits are expected to decline, then in most cases the share price will decline over time as well. In addition, if the company pays dividends it will also likely need to reduce or cut them, striking a dual blow to total shareholder returns. Currently, the following risks have been identified for the company: Major Risk Earnings are forecast to decline by an average of 24% per year for the foreseeable future. Minor Risks Dividend is not well covered by earnings (116% payout ratio). Share price has been volatile over the past 3 months (8.9% average weekly change). Profit margins are more than 30% lower than last year (11% net profit margin). Shareholders have been diluted in the past year (10.0% increase in shares outstanding).
Recent Insider Transactions • Dec 31Insider recently bought €3.0m worth of stockOn the 22nd of December, Garibaldi Thohir bought around 99m shares on-market at roughly €0.031 per share. This transaction amounted to 12% of their direct individual holding at the time of the trade. This was the largest purchase by an insider in the last 3 months. This was the only on-market transaction from insiders over the last 12 months.
Reported Earnings • Oct 20Third quarter 2023 earnings released: EPS: US$0 (vs US$0.003 in 3Q 2022)Third quarter 2023 results: EPS: US$0 (down from US$0.003 in 3Q 2022). Revenue: US$64.5m (down 69% from 3Q 2022). Net income: US$5.79m (down 85% from 3Q 2022). Profit margin: 9.0% (down from 18% in 3Q 2022). The decrease in margin was driven by lower revenue. Revenue is expected to decline by 10% p.a. on average during the next 3 years, while revenues in the Chemicals industry in Germany are expected to grow by 1.9%. Over the last 3 years on average, earnings per share has increased by 86% per year but the company’s share price has increased by 129% per year, which means it is tracking significantly ahead of earnings growth.
Buying Opportunity • Aug 01Now 29% undervalued after recent price dropOver the last 90 days, the stock is down 6.1%. The fair value is estimated to be €0.043, however this is not to be taken as a buy recommendation but rather should be used as a guide only. Revenue has grown by 50% over the last 3 years. Meanwhile, the company has become profitable. Revenue is forecast to decline by 29% in 2 years. Earnings is forecast to decline by 17% in the next 2 years.
Reported Earnings • Jul 30Second quarter 2023 earnings released: EPS: US$0 (vs US$0.003 in 2Q 2022)Second quarter 2023 results: EPS: US$0 (down from US$0.003 in 2Q 2022). Revenue: US$80.3m (down 58% from 2Q 2022). Net income: US$863.6k (down 98% from 2Q 2022). Profit margin: 1.1% (down from 21% in 2Q 2022). The decrease in margin was driven by lower revenue. Revenue is expected to decline by 13% p.a. on average during the next 3 years, while revenues in the Chemicals industry in Germany are expected to grow by 1.3%. Over the last 3 years on average, earnings per share has increased by 104% per year but the company’s share price has increased by 112% per year, which means it is tracking significantly ahead of earnings growth.
Reported Earnings • Apr 30First quarter 2023 earnings released: EPS: US$0 (vs US$0.002 in 1Q 2022)First quarter 2023 results: EPS: US$0 (down from US$0.002 in 1Q 2022). Revenue: US$87.8m (down 45% from 1Q 2022). Net income: US$3.11m (down 88% from 1Q 2022). Profit margin: 3.5% (down from 16% in 1Q 2022). The decrease in margin was driven by lower revenue. Revenue is expected to decline by 8.7% p.a. on average during the next 3 years, while revenues in the Chemicals industry in Germany are expected to grow by 1.7%. Over the last 3 years on average, earnings per share has increased by 116% per year whereas the company’s share price has increased by 113% per year.
Upcoming Dividend • Mar 21Upcoming dividend of Rp45.00 per share at 0.5% yieldEligible shareholders must have bought the stock before 28 March 2023. Payment date: 05 April 2023. Payout ratio is a comfortable 4.8% and this is well supported by cash flows. Trailing yield: 0.5%. Lower than top quartile of German dividend payers (4.9%). Lower than average of industry peers (5.8%).
Reported Earnings • Feb 22Full year 2022 earnings released: EPS: US$0.009 (vs US$0.001 in FY 2021)Full year 2022 results: EPS: US$0.009 (up from US$0.001 in FY 2021). Revenue: US$731.5m (up 141% from FY 2021). Net income: US$138.8m (up US$124.9m from FY 2021). Profit margin: 19% (up from 4.6% in FY 2021). The increase in margin was driven by higher revenue. Revenue is expected to decline by 15% p.a. on average during the next 3 years, while revenues in the Chemicals industry in Germany are expected to grow by 1.4%. Over the last 3 years on average, earnings per share has increased by 119% per year but the company’s share price has only increased by 80% per year, which means it is significantly lagging earnings growth.
お知らせ • Feb 11PT Surya Esa Perkasa Tbk, Annual General Meeting, Mar 15, 2023PT Surya Esa Perkasa Tbk, Annual General Meeting, Mar 15, 2023, at 15:00 SE Asia Standard Time.
お知らせ • Jan 04PT Surya Esa Perkasa Tbk agreed to acquire an additional unknown stake in PT Panca Amara Utama from Garibaldi Thohir.PT Surya Esa Perkasa Tbk agreed to acquire an additional unknown stake in PT Panca Amara Utama from Garibaldi Thohir on January 2, 2023. The proceeds from private placement were used for this acquisition.
Board Change • Nov 16No independent directorsFollowing the recent departure of a director, there are no independent directors on the board. The company's board is composed of: No independent directors. 5 non-independent directors. Independent President Commissioner Hamid Awaluddin was the last independent director to join the board, commencing their role in 2012. The company's lack of independent directors is a risk according to the Simply Wall St Risk Model.
Reported Earnings • Oct 12Third quarter 2022 earnings released: EPS: US$0.003 (vs US$0.001 in 3Q 2021)Third quarter 2022 results: EPS: US$0.003 (up from US$0.001 in 3Q 2021). Revenue: US$206.1m (up 103% from 3Q 2021). Net income: US$37.7m (up 100% from 3Q 2021). Profit margin: 18% (in line with 3Q 2021). Revenue is expected to decline by 5.5% p.a. on average during the next 3 years, while revenues in the Chemicals industry in Germany are expected to grow by 1.3%. Over the last 3 years on average, earnings per share has increased by 88% per year but the company’s share price has only increased by 73% per year, which means it is significantly lagging earnings growth.
Reported Earnings • Jul 28Second quarter 2022 earnings releasedSecond quarter 2022 results: Revenue: US$191.9m (up 173% from 2Q 2021). Net income: US$41.0m (up US$58.1m from 2Q 2021). Profit margin: 21% (up from net loss in 2Q 2021). The move to profitability was driven by higher revenue. Over the next year, revenue is forecast to grow 27%, compared to a 7.3% growth forecast for the industry in Germany. Over the last 3 years on average, earnings per share has increased by 31% per year but the company’s share price has increased by 69% per year, which means it is tracking significantly ahead of earnings growth.
Buying Opportunity • Jul 05Now 31% undervalued after recent price dropOver the last 90 days, the stock is down 38%. The fair value is estimated to be €0.072, however this is not to be taken as a buy recommendation but rather should be used as a guide only. Revenue has grown by 15% over the last 3 years. Meanwhile, the company has become profitable. Revenue is forecast to grow by 50% in 2 years. Earnings is forecast to grow by 233% in the next 2 years.
Buying Opportunity • Jun 17Now 20% undervaluedOver the last 90 days, the stock is up 13%. The fair value is estimated to be €0.061, however this is not to be taken as a buy recommendation but rather should be used as a guide only. Revenue has grown by 15% over the last 3 years. Meanwhile, the company has become profitable. Revenue is forecast to grow by 50% in 2 years. Earnings is forecast to grow by 233% in the next 2 years.
Reported Earnings • Jun 01First quarter 2022 earnings released: EPS: US$0.002 (vs US$0 in 1Q 2021)First quarter 2022 results: EPS: US$0.002 (up from US$0 in 1Q 2021). Revenue: US$159.0m (up 132% from 1Q 2021). Net income: US$25.9m (up 304% from 1Q 2021). Profit margin: 16% (up from 9.4% in 1Q 2021). The increase in margin was driven by higher revenue. Over the next year, revenue is forecast to grow 80%, compared to a 52% growth forecast for the industry in Germany. Over the last 3 years on average, earnings per share has fallen by 48% per year but the company’s share price has increased by 72% per year, which means it is well ahead of earnings.
Board Change • Apr 27No independent directorsFollowing the recent departure of a director, there are no independent directors on the board. The company's board is composed of: No independent directors. 5 non-independent directors. Independent Commissioner Ida Bagus Supancana was the last independent director to join the board, commencing their role in 2011. The company's lack of independent directors is a risk according to the Simply Wall St Risk Model.
Buying Opportunity • Mar 09Now 22% undervaluedOver the last 90 days, the stock is up 131%. The fair value is estimated to be US$0.052, however this is not to be taken as a buy recommendation but rather should be used as a guide only. Revenue has grown by 13% per annum over the last 3 years. The company has become profitable over the last year.
Reported Earnings • Nov 27Third quarter 2021 earnings: EPS in line with analyst expectations despite revenue beatThird quarter 2021 results: EPS: US$0.001 (up from US$0.001 loss in 3Q 2020). Revenue: US$101.6m (up 261% from 3Q 2020). Net income: US$18.9m (up US$26.6m from 3Q 2020). Profit margin: 19% (up from net loss in 3Q 2020). The move to profitability was driven by higher revenue. Revenue exceeded analyst estimates by 14%. Over the last 3 years on average, the company's share price growth rate has exceeded its earnings growth rate by 122 percentage points per year, which is a significant difference in performance.
Reported Earnings • Aug 31Second quarter 2021 earnings released: US$0.001 loss per share (vs US$0.001 loss in 2Q 2020)The company reported a decent second quarter result with improved revenues, although losses increased and control over costs was weaker. Second quarter 2021 results: Revenue: US$70.4m (up 114% from 2Q 2020). Net loss: US$17.1m (loss widened 120% from 2Q 2020). Over the last 3 years on average, the company's share price growth rate has exceeded its earnings growth rate by 148 percentage points per year, which is a significant difference in performance.
Reported Earnings • Oct 29Third quarter earnings releasedOver the last 12 months the company has reported total losses of US$16.4m, with earnings decreasing by US$43.0m from the prior year. Total revenue was US$177.4m over the last 12 months, down 27% from the prior year.
お知らせ • Sep 21PT Surya Esa Perkasa Tbk(IDX:ESSA) dropped from S&P Global BMI IndexPT Surya Esa Perkasa Tbk(IDX:ESSA) dropped from S&P Global BMI Index